Novo Nordisk has escalated the patent battle over semaglutide in India, moving the Delhi High Court to restrain Sun Pharma from launching its generic version of the diabetes and weight-loss drug.

The Danish drugmaker is looking to protect its market position around semaglutide, the active ingredient behind its blockbuster product Ozempic, as patent challenges mount in the country.

The company currently holds two key patents related to semaglutide. One expired in September 2024 while the second is scheduled to lapse in March 2026. The approaching expiry has triggered intense interest among Indian pharmaceutical companies eager to tap into the rapidly expanding market for diabetes and obesity therapies. Sun Pharma, in its recent quarterly earnings, had openly spoken about the opportunity

See Full Page